Molecular Genetic Basis of Invasive Breast Cancer Risk Associated With Lobular Carcinoma in Situ
| Status: | Active, not recruiting |
|---|---|
| Conditions: | Breast Cancer, Cancer |
| Therapuetic Areas: | Oncology |
| Healthy: | No |
| Age Range: | Any |
| Updated: | 8/11/2018 |
| Start Date: | October 2001 |
| End Date: | October 2019 |
This study is being done in order to better understand the biology of an abnormal lesion
found in breast tissue called "lobular carcinoma in situ" (LCIS). We are interested in
studying LCIS. The LCIS is not a cancer itself, but is a marker for an increased risk of
cancer. We would like to look for LCIS in breast tissue removed during surgery from patients
with cancer or at high risk for cancer. If LCIS is found, we will search for genes that are
expressed (turned on or off) differently than in normal breast tissue. The identification of
such genes would help us better understand the biology of LCIS, and its possible relationship
to breast cancer.
found in breast tissue called "lobular carcinoma in situ" (LCIS). We are interested in
studying LCIS. The LCIS is not a cancer itself, but is a marker for an increased risk of
cancer. We would like to look for LCIS in breast tissue removed during surgery from patients
with cancer or at high risk for cancer. If LCIS is found, we will search for genes that are
expressed (turned on or off) differently than in normal breast tissue. The identification of
such genes would help us better understand the biology of LCIS, and its possible relationship
to breast cancer.
LCIS) is a monoclonal pathologic entity which is subject to characterization at the molecular
genetic level, and that these molecular genetic alterations may be used to predict the
subsequent development of invasive breast cancer. Prophylactic mastectomy specimens from
women with multifocal LCIS, and invasive breast cancer specimens which display coexisting
LCIS, will be examined for X-chromosome inactivation patterns and loss of heterozygosity to
assess for monoclonality. If clonality is present, we will assess for microsatellite
instability, and a microarray-based comparative genomic hybridization (CGH) technique will be
used to identify genetic alterations present in LCIS. Lastly, LCIS biopsy specimens from
untreated patients who, after follow-up did or did not develop invasive breast cancer, will
be evaluated to determine whether the nature or extent of any identified genetic alterations
can be correlated with the subsequent development of invasive breast cancer. We hypothesize
that a fraction of LCIS lesions will reflect a monoclonal origin, that those lesions of
monoclonal origin will display evidence of specific molecular genetic alterations, and that
these specific alterations will correlate with the likelihood of the subsequent development
of invasive breast carcinoma.
genetic level, and that these molecular genetic alterations may be used to predict the
subsequent development of invasive breast cancer. Prophylactic mastectomy specimens from
women with multifocal LCIS, and invasive breast cancer specimens which display coexisting
LCIS, will be examined for X-chromosome inactivation patterns and loss of heterozygosity to
assess for monoclonality. If clonality is present, we will assess for microsatellite
instability, and a microarray-based comparative genomic hybridization (CGH) technique will be
used to identify genetic alterations present in LCIS. Lastly, LCIS biopsy specimens from
untreated patients who, after follow-up did or did not develop invasive breast cancer, will
be evaluated to determine whether the nature or extent of any identified genetic alterations
can be correlated with the subsequent development of invasive breast cancer. We hypothesize
that a fraction of LCIS lesions will reflect a monoclonal origin, that those lesions of
monoclonal origin will display evidence of specific molecular genetic alterations, and that
these specific alterations will correlate with the likelihood of the subsequent development
of invasive breast carcinoma.
Inclusion Criteria:
- multifocal lobular carcinoma in situ treated with prophylactic mastectomy or
lumpectomy
- invasive breast cancer (lobular or ductal) with coexisting lobular carcinoma in situ
treated with mastectomy or lumpectomy
- biopsy proven, untreated lobular carcinoma in situ
- invasive lobular cancer with or without coexisting lobular carcinoma in situ treated
with mastectomy or lumpectomy
Exclusion Criteria:
- no paraffin blocks available
- no residual lobular carcinoma in situ in paraffin blocks
We found this trial at
1
site
Memorial Sloan Kettering Cancer Center Memorial Sloan Kettering Cancer Center — the world's oldest and...
Click here to add this to my saved trials
